Biomarkers of graft-vs-host disease: Understanding and applications for the future

doi:10.5500/wjt.v11.i8.335

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6684)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

350

WORD

127

HTML

3299

Figures (1-2)

347

Sum=4123

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

424

Download

847

Sum=1271

Publishing Process of This Article

Item

Count

Browse

407

Download

883

Sum=1290

Aug 18, 2021 (publication date) through Nov 2, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Transplant. Aug 18, 2021; 11(8): 335-343
Published online Aug 18, 2021. doi: 10.5500/wjt.v11.i8.335

Biomarkers of graft-vs-host disease: Understanding and applications for the future

Masayuki Nagasawa

Masayuki Nagasawa, Department of Pediatrics, Musashino Red Cross Hospital, Musashino City 180-8610, Tokyo, Japan

Author contributions: Nagasawa M conceptualized the idea, reviewed the literature, and wrote the main draft of the manuscript.

Supported by partly a Grant-in-Aid for Scientific Research (KAKENHI) Grant, No. 15K09639.

Conflict-of-interest statement: I have no conflict-of-interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Masayuki Nagasawa, MD, PhD, Chief Doctor, Department of Pediatrics, Musashino Red Cross Hospital, 1-26-1, Kyonan-cho, Musashino City 180-8610, Tokyo, Japan. mnagasawa.ped@tmd.ac.jp

Received: February 16, 2021
Peer-review started: February 16, 2021
First decision: May 14, 2021
Revised: May 25, 2021
Accepted: August 10, 2021
Article in press: August 10, 2021
Published online: August 18, 2021
Processing time: 177 Days and 2 Hours

Core Tip

Core Tip: Graft-vs-host disease (GVHD) is the most unfavorable complication of hematopoietic stem cell transplantation (HSCT). Minimizing acute GVHD and inducing its chronic form is necessary to achieve good clinical outcomes in HSCT. GVHD consists of inflammation induced by the conditioning regimen, the alloimmune response of the T lymphocytes, and organ damage due to the graft-vs-host reaction. Biological factors have been comprehensively analyzed to identify novel combinations of biomarkers that predict acute GVHD severity and prognosis more efficiently. Currently, there are no useful biomarkers that can predict the severity and prognosis of chronic GVHD or serve a practical clinical use.